object
ribavirin
broad
spectrum
nucleosid
analogu
efficaci
treatment
sever
viral
infect
recent
sever
acut
respiratori
syndrom
sar
outbreak
ribavirin
use
variou
countri
novel
coronaviru
conduct
retrospect
analysi
assess
efficaci
ribavirin
treatment
sar
singapor
method
total
case
analys
ninetyseven
patient
receiv
ribavirin
mean
day
ill
clinic
laboratori
paramet
taken
start
ribavirin
treatment
compar
day
paramet
patient
treatment
two
group
compar
use
fisher
exact
test
student
ttest
multivari
analysi
perform
use
cox
regress
model
death
outcom
interest
result
treatment
group
younger
women
symptom
myalgia
p
crude
death
rate
control
p
treatment
group
correct
age
male
sex
lactat
dehydrogenas
level
steroid
use
hazard
ratio
ci
p
conclus
retrospect
uncontrol
cohort
analysi
use
ribavirin
appear
confer
benefit
patient
sar
keyword
mortal
ribavirin
sever
acut
respiratori
syndrom
singapor
ribavirin
broad
spectrum
synthet
nucleosid
analogu
efficaci
treatment
respiratori
syncyti
viru
infect
among
vulner
children
lassa
fever
haemorrhag
fever
renal
syndrom
crimeancongo
haemorrhag
fever
sever
adenoviru
infect
immunocompromis
patient
combin
hepat
c
infect
broad
spectrum
low
rel
toxic
often
test
compassion
basi
new
reemerg
viral
infect
thu
use
sever
countri
dramat
appear
sever
acut
respiratori
syndrom
sar
east
asia
includ
singapor
canada
perform
retrospect
cohort
studi
assess
effect
ribavirin
use
patient
sar
patient
identifi
exist
hospit
registri
probabl
sar
admit
march
may
diagnosi
sar
base
world
health
organ
criteria
time
acut
ill
use
ribavirin
doctordepend
oral
ribavirin
dose
g
three
time
day
intraven
ribavirin
mg
everi
h
sicker
patient
could
take
per
os
rout
administr
vari
depend
whether
patient
could
toler
feed
collect
data
demograph
present
symptom
sign
laboratori
result
day
admiss
univari
analysi
use
fisher
exact
test
student
ttest
compar
data
patient
ribavirin
multivari
analysi
use
cox
regress
model
provid
crude
adjust
hazard
ratio
use
ribavirin
aim
adjust
covari
distribut
unevenli
two
group
may
relat
outcom
death
primari
outcom
interest
cox
regress
analysi
use
compar
surviv
time
ribavirin
surviv
time
defin
interv
date
onset
date
death
except
three
patient
use
august
last
sar
patient
discharg
hospit
date
last
followup
patient
surviv
sar
three
patient
discharg
aliv
sar
subsequ
die
caus
surviv
time
thu
defin
interv
date
onset
date
last
known
followup
hospit
adjust
known
possibl
confound
done
stage
highlight
increment
effect
confound
use
ribavirin
data
analys
use
stata
version
softwar
stata
corp
colleg
station
tx
usa
test
conduct
level
signific
also
attempt
identifi
complic
drug
treatment
treatment
group
name
myocardi
injuri
anaemia
myocardi
injuri
defin
serial
elev
creatinin
kinas
creatinin
kinas
progress
rise
electrocardiogram
chang
develop
elev
st
segment
q
wave
anaemia
fall
gdl
haemoglobin
day
treatment
singapor
case
probabl
sar
identifi
case
admit
hospit
diagnos
probabl
sar
acut
period
ill
case
identifi
retrospect
posit
serolog
test
result
done
followup
total
case
avail
analysi
patient
receiv
ribavirin
use
ribavirin
throughout
epidem
repres
figur
mean
start
point
ribavirin
treatment
day
onset
ill
treatment
durat
mean
day
compar
result
clinic
laboratori
investig
start
ribavirin
treatment
correspond
paramet
patient
receiv
ribavirin
day
ill
clinic
laboratori
result
day
avail
result
day
use
instead
group
share
similar
characterist
admiss
treatment
group
fewer
male
younger
patient
symptom
myalgia
patient
group
better
oxygen
satur
measur
puls
oximetri
admiss
compar
control
clinic
laboratori
result
taken
start
ribavirin
treatment
group
vs
day
ill
control
group
similar
tabl
three
patient
posit
serolog
result
sarscov
three
diagnos
probabl
sar
hospit
none
receiv
ribavirin
time
data
analysi
patient
studi
discharg
die
ill
crude
death
rate
compar
two
group
treatment
group
control
p
signific
differ
proport
patient
admit
intens
care
unit
icu
two
group
tabl
hazard
ratio
death
among
ribavirin
ci
p
compar
control
group
uneven
distribut
male
sex
older
men
known
marker
poorer
prognosi
booth
et
al
lee
et
al
wong
et
al
karlberg
et
al
enzym
lactat
dehydrogenas
ldh
also
identifi
predictor
poorer
prognosi
sever
studi
booth
et
al
lee
et
al
wong
et
al
adjust
factor
steroid
use
hazard
ratio
death
ci
p
ribavirin
tabl
statist
signific
differ
two
group
acut
myocardi
infarct
anaemia
hong
kong
canada
ribavirin
use
treat
sar
want
specif
form
treatment
tsang
et
al
justif
use
came
previou
experi
mous
hepat
coronaviru
ning
et
al
togeth
use
steroid
potenti
antivir
immunomodulatori
effect
ribavirin
would
appear
appropri
propos
immunopatholog
damag
second
week
sar
peiri
et
al
howev
use
challeng
control
studi
avail
vitro
evid
suggest
drug
activ
sarscov
concentr
ribavirinsensit
virus
mmwr
toronto
ribavirin
use
without
steroid
routin
patient
booth
et
al
receiv
steroid
concurr
major
receiv
ribavirin
within
first
h
hospit
patient
given
load
dose
follow
decreas
mainten
dose
treatment
durat
mean
day
author
report
poorer
outcom
death
icu
admiss
without
mechan
ventil
patient
ribavirin
although
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
knowl
et
al
hong
kong
combin
treatment
ribavirin
steroid
given
patient
fever
radiograph
abnorm
histori
contact
index
sar
patient
et
al
dosag
regimen
similar
except
prednisolon
given
addit
na
mean
day
ribavirin
sd
na
na
tw
total
white
plt
platelet
ldh
lactat
dehydrogenas
fio
oxygen
express
fraction
inspir
air
sao
satur
oxygen
icu
intens
care
unit
na
avail
paramet
taken
start
treatment
ribavirin
day
control
group
result
avail
day
paramet
use
instead
myocardi
injuri
defin
serial
elev
creatinin
kinas
creatinin
kinas
progress
rise
electrocardiogram
chang
develop
elev
st
segment
q
wave
admiss
till
day
ill
anaemia
defin
fall
gdl
haemoglobin
admiss
till
day
ill
pvalu
student
ttest
unless
otherwis
indic
pvalu
fisher
exact
test
ribavirin
dose
mgkg
bodi
weight
patient
receiv
combin
therapi
compar
efficaci
data
treatment
control
group
avail
singapor
dose
regimen
parallel
hong
kong
studi
steroid
routin
administ
togeth
ribavirin
patient
receiv
ribavirin
steroid
concurr
ribavirin
offer
manag
doctor
discret
within
h
confirm
diagnosi
probabl
sar
unlik
canadian
patient
start
ribavirin
mean
day
ill
treatment
protocol
requir
patient
start
ribavirin
result
two
group
patient
hospit
two
group
studi
subject
dissimilar
control
group
compris
older
male
p
risk
factor
poorer
prognosi
lee
et
al
karlberg
et
al
unexpect
studi
design
ldh
welldescrib
predictor
sever
ill
henc
use
level
correct
sever
ill
start
ribavirin
use
ldh
level
start
ribavirin
treatment
group
compar
level
day
ill
control
group
mean
start
date
ribavirin
day
ill
hazard
ratio
ci
p
associ
ribavirin
correct
predictor
mortal
line
canadian
studi
thu
surpris
health
canada
recommend
use
routin
patient
probabl
sar
health
canada
use
steroid
antibacteri
antibiot
differ
two
group
steroid
use
defin
ever
treat
hydrocortison
prednisolon
methylprednisolon
singli
combin
antibiot
use
refer
administr
antibacteri
agent
eg
ceftriaxon
erythromycin
clarithromycin
amoxicillinclavulan
levofloxacin
treatment
pneumonia
patient
concurr
use
steroid
treatment
group
fewer
concurr
use
antibiot
steroid
frequent
use
combin
ribavirin
earlier
part
epidem
control
group
steroid
use
togeth
intraven
cglobulin
new
treatment
regimen
later
part
epidem
correct
steroid
use
hazard
ratio
death
patient
treat
ribavirin
ci
p
earlier
part
epidem
patient
identifi
sar
base
exist
guidelin
epidemiolog
link
given
ribavirin
without
concurr
antibacteri
agent
account
fewer
patient
receiv
antibacteri
agent
treatment
group
group
patient
mild
diseas
recov
quickli
subsequ
death
nobodi
requir
icu
admiss
advers
effect
relat
use
ribavirin
welldescrib
complic
includ
haemolyt
anaemia
bone
marrow
suppress
elev
lactat
pyruv
level
hypocalcaemia
hypomagnesaemia
hyperammonaemia
pancreat
booth
et
al
report
patient
ribavirin
experienc
decreas
haemoglobin
patient
evid
haemolysi
prematur
discontinu
ribavirin
necessari
patient
studi
complic
myocardi
injuri
anaemia
differ
two
group
three
patient
myocardi
event
patient
decreas
haemoglobin
gdl
treatment
group
compar
four
respect
nontreat
group
caus
anaemia
establish
case
unabl
ascertain
number
patient
haemolyt
anaemia
secondari
use
ribavirin
studi
retrospect
analysi
two
group
patient
treat
differ
time
epidem
patient
receiv
ribavirin
admit
earli
epidem
appar
lack
clinic
efficaci
support
subsequ
vitro
report
led
declin
use
drug
differ
manag
practic
two
tempor
group
would
affect
interpret
result
use
steroid
dosag
rout
differ
throughout
epidem
also
chang
treatment
protocol
hospit
unpublish
analysi
observ
overal
surviv
outcom
improv
later
part
epidem
fewer
admit
icu
lower
apach
score
may
skew
result
favour
receiv
ribavirin
studi
use
inhospit
mortal
outcom
indic
effect
ribavirin
patient
eg
lung
function
time
defervesc
fever
infect
assess
limit
interpret
studi
retrospect
uncontrol
cohort
analysi
use
ribavirin
alon
appear
confer
benefit
patient
sar
consist
vitro
data
new
therapeut
option
tri
includ
immun
therapi
